Alvotech Reports Results from the Study of AVT05, Biosimilar Candidate to Simponi and Simponi Aria (golimumab)
Shots:
- Alvotech has announced top-line results from a PK trial investigating AVT05, a biosimilar candidate for Simponi & Simponi Aria (golimumab)
- The trial met its 1EP which was commenced by the company in May 2023 to compare the efficacy, safety, and immunogenicity of AVT05 and Simponi to treat adults with moderate to severe rheumatoid arthritis
- AVT05, mAb targeting TNF alpha, has not gained regulatory approval, and bio similarity is yet to be established by authorities
Ref: Alvotech | Image: Alvotech
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
